JASON KELLOGG: Open Payments
NPI 1952331530 · IRVINE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$463,035 in 516 payments from 14 companies in 2025. Trend: 2023 $428,923 · 2024 $432,271 · 2025 $463,035
Speaker / faculty: $366,336Travel & lodging: $67,000Consulting: $17,320Food & beverage: $12,378
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 124 | $112,618 |
| Vanda Pharmaceuticals Inc. | 88 | $87,135 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 65 | $67,049 |
| Janssen Pharmaceuticals, Inc | 68 | $67,030 |
| E.R. Squibb & Sons, L.L.C. | 52 | $53,470 |
| ACADIA Pharmaceuticals Inc | 60 | $35,925 |
| Otsuka America Pharmaceutical, Inc. | 40 | $30,204 |
| Teva Pharmaceuticals USA, Inc. | 9 | $9,274 |
| Luye Pharma (USA) Ltd. | 3 | $167 |
| Alkermes, Inc. | 3 | $67 |
Products named: INGREZZA, FANAPT, CAPLYTA, INVEGA SUSTENNA, COBENFY, NUPLAZID, REXULTI, AUSTEDO XR.
Industry payments across CA — which companies pay providers there.
